- Home
- LU vs NVCR Comparison
LU vs NVCR Comparison
Compare LU & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LU
- NVCR
- Stock Information
- Founded
- LU 2005
- NVCR 2000
- Country
- LU China
- NVCR Switzerland
- Employees
- LU N/A
- NVCR N/A
- Industry
- LU Finance: Consumer Services
- NVCR Medical/Dental Instruments
- Sector
- LU Finance
- NVCR Health Care
- Exchange
- LU Nasdaq
- NVCR Nasdaq
- Market Cap
- LU 2.4B
- NVCR 2.3B
- IPO Year
- LU 2020
- NVCR 2015
- Fundamental
- Price
- LU $3.10
- NVCR $22.09
- Analyst Decision
- LU Hold
- NVCR Buy
- Analyst Count
- LU 2
- NVCR 5
- Target Price
- LU $2.98
- NVCR $33.40
- AVG Volume (30 Days)
- LU 4.0M
- NVCR 700.2K
- Earning Date
- LU 03-20-2025
- NVCR 02-27-2025
- Dividend Yield
- LU 76.33%
- NVCR N/A
- EPS Growth
- LU N/A
- NVCR N/A
- EPS
- LU N/A
- NVCR N/A
- Revenue
- LU $4,671,260,668.00
- NVCR $577,738,000.00
- Revenue This Year
- LU N/A
- NVCR $19.97
- Revenue Next Year
- LU $1.48
- NVCR $2.83
- P/E Ratio
- LU N/A
- NVCR N/A
- Revenue Growth
- LU N/A
- NVCR 14.63
- 52 Week Low
- LU $2.00
- NVCR $11.70
- 52 Week High
- LU $4.94
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- LU 68.59
- NVCR 36.77
- Support Level
- LU $2.78
- NVCR $21.38
- Resistance Level
- LU $2.96
- NVCR $22.95
- Average True Range (ATR)
- LU 0.13
- NVCR 0.86
- MACD
- LU 0.06
- NVCR 0.01
- Stochastic Oscillator
- LU 88.83
- NVCR 34.25
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.